Basic and applied study on AIDS-therapy using hybrid liposomes
| Project/Area Number |
24656509
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biofunction/Bioprocess
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
UEOKA Ryuichi 崇城大学, 生物生命学部, 客員研究員 (70099076)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | リポソーム / エイズ / エイズ関連腫瘍 / 細胞膜流動性 / 細胞膜 / ナノメディシン / 脂質 |
|---|
| Research Abstract |
We have produced hybrid liposomes (HL) which can be prepared by sonication of vesicular and micellar molecules in a buffer solution. We have investigated the anti-AIDS effects of HL and following results are obtained. (1)Remarkably high therapeutic effects were obtained in the mouse models of adult T-cell leukemia/lymphoma (ATLL) after the treatment with HL on the basis of relative organ weight and histological analysis using hematoxylin-eosin (HE) and immunohistochemical staining of CD4 and CD25. Prolonged survival was obtained in the mouse models of ATLL after the treatment with HL. (2)The anti-HIV-1 activity of cepharanthine (CEP), a natural product derived from Stephania cepharantha Hayata, was evaluated. CEP stabilized plasma membrane fluidity and inhibited HIV-1 envelope-dependent cell-to-cell fusion of HIV-1-infected cells as well as cell-free infection. These findings suggest that HL and CEP should be a new type of nanomedicinal anti-AIDS drug that targets cell-membranes.
|
Report
(3 results)
Research Products
(60 results)
